A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An (Q27302763)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An |
scientific article |
Statements
1 reference
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An (English)
1 reference
Carol Aghajanian
1 reference
Robert L Coleman
1 reference
Michael W Sill
1 reference
Katherine Bell-McGuinn
1 reference
Heidi J Gray
1 reference
Krishnansu S Tewari
1 reference
Steven C Rubin
1 reference
Thomas J Rutherford
1 reference
John K Chan
1 reference
Alice Chen
1 reference
Elizabeth M Swisher
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference